Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug curb severe bleeding in a rare genetic disorder?

NCT ID NCT07772050

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This study looks back at the medical records of 244 adults in France with hereditary hemorrhagic telangiectasia (HHT), also called Rendu-Osler disease, who were treated with the drug bevacizumab. The goal is to describe how the drug was used and to measure its impact on bleeding, as reflected by the number of red blood cell transfusions and hemoglobin levels. By analyzing real-world data from 2009 to 2024, researchers hope to better understand the drug's potential benefits for managing this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bevacizumab (an anti-VEGF antibody)
What this could lead to
If successful, this analysis could strengthen the evidence for using bevacizumab to reduce bleeding and transfusion needs in people with HHT.
What could go wrong
This is a retrospective review, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection and missing data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

244 people

The number who actually took part.

Started

Jan 2009

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

A Total of 317 patients will be included , all of whom were adults aged 18 years or older, diagnosed with hereditary haemorrhagic telangiectasia, and have received systemic bevacizumab exclusively for HHT-related manifestations.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Adult over 18 years of age * Rendu-Osler disease treated with bevacizumab prescribed for this condition * Treated and followed in France Exclusion Criteria: * \- Patient opposition to data use

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia (HHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia Cardiac Output, High Hemorrhage hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary hemorrhagic telangiectasia (HHT) Rendu osler disease

Contacts and locations

Locations

  • Hôpital Femme Mère Enfant

    Bron, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.